This article is more than 5 years old. Information may no longer be current.
Eyevance Pharmaceuticals established with Zerviate licensing agreement
Click Here to Manage Email Alerts
Former Sun Pharmaceutical leaders Jerry St. Peter and Jason Werner have formed Eyevance Pharmaceuticals, a new company focusing on ophthalmic pharmaceuticals, according to a press release.
The company, founded this month, recently entered into an exclusive licensing agreement with Nicox for U.S. commercialization of Zerviate (cetirizine ophthalmic solution 0.24%), the first topical formulation of cetirizine approved for ocular itching associated with allergic conjunctivitis.
St. Peter, who was previously vice president and head of ophthalmic business at Sun, will serve as the company’s CEO, while Werner, who was previously vice president of strategy and commercial development at Sun, is its chief operating officer.
“As a new entrant to the ophthalmic space, our mission is clear and focused: to develop and commercialize innovative, impactful eye care products that improve vision, restore health and elevate patient quality of life. The opportunity to commercialize Zerviate, a clinically proven and time-tested molecule, for patients suffering from allergic conjunctivitis represents the first momentous step towards achieving our mission,” St. Peter said in the release.